Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA
Status:
Completed
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring
activating epidermal growth factor receptor (EGFR) mutations (cohort 1) and those harboring
T790M (cohort 2) which were detected from circulating tumor DNA